GlaxoSmithKline's Nucala Approved in Europe for Additional Diseases
17 November 2021 - 6:55PM
Dow Jones News
By Sabela Ojea
GlaxoSmithKline PLC said Wednesday that its Nucala monoclonal
antibody has been approved in Europe by the European Commission for
three additional eosinophil-driven diseases.
The British pharma major said this antibody is the first
approved targeted treatment for use in four of these
eosinophil-driven conditions.
Eosinophil-driven diseases are inflammatory conditions linked to
elevated levels of eosinophils, a type of white blood cell, the
company said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 17, 2021 02:40 ET (07:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
